Analysts Offer Predictions for Sarepta Therapeutics, Inc.’s FY2024 Earnings (NASDAQ:SRPT)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Research analysts at William Blair lowered their FY2024 EPS estimates for shares of Sarepta Therapeutics in a research report issued to clients and investors on Wednesday, May 1st. William Blair analyst T. Lugo now expects that the biotechnology company will earn $6.10 per share for the year, down from their previous estimate of $6.66. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $2.23 per share.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.73 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.84. The company had revenue of $413.50 million during the quarter, compared to analysts’ expectations of $375.52 million. Sarepta Therapeutics had a net margin of 1.20% and a return on equity of 2.20%. The firm’s quarterly revenue was up 63.1% on a year-over-year basis. During the same period in the previous year, the company earned ($1.44) EPS.

A number of other equities research analysts have also recently commented on SRPT. Barclays increased their target price on shares of Sarepta Therapeutics from $141.00 to $185.00 and gave the company an “overweight” rating in a research report on Thursday, February 29th. BMO Capital Markets began coverage on shares of Sarepta Therapeutics in a research report on Wednesday, January 31st. They set an “outperform” rating and a $170.00 target price for the company. UBS Group increased their target price on shares of Sarepta Therapeutics from $164.00 to $167.00 and gave the company a “buy” rating in a research report on Friday, March 1st. Needham & Company LLC reissued a “buy” rating and set a $166.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, May 2nd. Finally, Evercore ISI increased their target price on shares of Sarepta Therapeutics from $108.00 to $138.00 and gave the company an “in-line” rating in a research report on Tuesday, February 20th. Four research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $160.60.

Sarepta Therapeutics Price Performance

Sarepta Therapeutics stock opened at $136.04 on Monday. The firm has a 50-day moving average of $125.47 and a two-hundred day moving average of $111.07. Sarepta Therapeutics has a 1 year low of $55.25 and a 1 year high of $159.89. The stock has a market cap of $12.86 billion, a price-to-earnings ratio of 1,236.73 and a beta of 0.95. The company has a debt-to-equity ratio of 1.18, a current ratio of 4.05 and a quick ratio of 3.44.

Insider Buying and Selling at Sarepta Therapeutics

In other Sarepta Therapeutics news, insider Dallan Murray sold 3,635 shares of the business’s stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $140.00, for a total value of $508,900.00. Following the transaction, the insider now directly owns 18,125 shares in the company, valued at approximately $2,537,500. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CFO Ian Michael Estepan sold 1,200 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $128.30, for a total transaction of $153,960.00. Following the sale, the chief financial officer now directly owns 39,114 shares of the company’s stock, valued at approximately $5,018,326.20. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Dallan Murray sold 3,635 shares of the business’s stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $140.00, for a total transaction of $508,900.00. Following the transaction, the insider now owns 18,125 shares of the company’s stock, valued at approximately $2,537,500. The disclosure for this sale can be found here. Insiders have sold 25,731 shares of company stock worth $3,248,319 in the last ninety days. 7.70% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Vanguard Group Inc. boosted its stake in Sarepta Therapeutics by 2.8% during the 4th quarter. Vanguard Group Inc. now owns 8,816,124 shares of the biotechnology company’s stock worth $850,139,000 after purchasing an additional 243,180 shares during the period. Capital International Investors raised its position in Sarepta Therapeutics by 160.0% during the 4th quarter. Capital International Investors now owns 4,741,485 shares of the biotechnology company’s stock worth $457,221,000 after buying an additional 2,917,797 shares during the last quarter. Avoro Capital Advisors LLC raised its position in Sarepta Therapeutics by 7.9% during the 4th quarter. Avoro Capital Advisors LLC now owns 4,344,444 shares of the biotechnology company’s stock worth $418,935,000 after buying an additional 319,444 shares during the last quarter. Wellington Management Group LLP raised its position in Sarepta Therapeutics by 5.6% during the 4th quarter. Wellington Management Group LLP now owns 4,127,610 shares of the biotechnology company’s stock worth $398,025,000 after buying an additional 217,810 shares during the last quarter. Finally, Norges Bank purchased a new position in Sarepta Therapeutics during the 4th quarter worth $80,697,000. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.